Literature DB >> 9003507

Refinement of the dominant optic atrophy locus (OPA1) to a 1.4-cM interval on chromosome 3q28-3q29, within a 3-Mb YAC contig.

A Jonasdottir1, H Eiberg, B Kjer, P Kjer, T Rosenberg.   

Abstract

Dominant optic atrophy, type Kjer, is an autosomal dominant eye disease that is characterized by progressive optic atrophy with onset in early childhood, decrease of visual acuity, colour vision defects and centrocecal scotoma. By examination of 5 Danish families and the use of polymorphic markers, we have refined the localization of the OPA1 locus and assigned it to a 1.4-cM interval on chromosome 3q28-3q29, between markers D3S3669 and D3S3562. This localizes the gene on a 3-Mb YAC contig covering the disease locus. We have also located a possible candidate gene HRY to this contig.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9003507     DOI: 10.1007/s004390050323

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  4 in total

Review 1.  Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy.

Authors:  M Votruba; A T Moore; S S Bhattacharya
Journal:  J Med Genet       Date:  1998-10       Impact factor: 6.318

Review 2.  A review of primary hereditary optic neuropathies.

Authors:  M Votruba; S Aijaz; A T Moore
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

3.  Characterization of two novel intronic OPA1 mutations resulting in aberrant pre-mRNA splicing.

Authors:  Ramona Bolognini; Christina Gerth-Kahlert; Mathias Abegg; Deborah Bartholdi; Nicolas Mathis; Veit Sturm; Sabina Gallati; André Schaller
Journal:  BMC Med Genet       Date:  2017-02-28       Impact factor: 2.103

4.  Dominant optic atrophy in Denmark - report of 15 novel mutations in OPA1, using a strategy with a detection rate of 90%.

Authors:  Gitte J Almind; Jakob Ek; Thomas Rosenberg; Hans Eiberg; Michael Larsen; Lucamp Lucamp; Karen Brøndum-Nielsen; Karen Grønskov
Journal:  BMC Med Genet       Date:  2012-08-02       Impact factor: 2.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.